# Olaparib In Metastatic Breast Cancer

> **NCT03344965** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Beth Israel Deaconess Medical Center** · enrollment: 114 (estimated)

## Conditions studied

- Metastatic Breast Cancer
- Invasive Breast Cancer
- Somatic Mutation Breast Cancer (BRCA1)
- Somatic Mutation Breast Cancer (BRCA2)
- CHEK2 Gene Mutation
- ATM Gene Mutation
- PALB2 Gene Mutation
- RAD51 Gene Mutation
- BRIP1 Gene Mutation
- NBN Gene Mutation

## Interventions

- **DRUG:** Olaparib

## Key facts

- **NCT ID:** NCT03344965
- **Lead sponsor:** Beth Israel Deaconess Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-04-01
- **Primary completion:** 2025-07-30
- **Final completion:** 2026-06-30
- **Target enrollment:** 114 (ESTIMATED)
- **Last updated:** 2026-01-05

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03344965

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03344965, "Olaparib In Metastatic Breast Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03344965. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*